MedTrace Logo

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-03-09

No results posted yet for this study

Summary

The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.

Conditions

  • Healthy

Interventions

DRUG

Naloxone

Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push

DRUG

Delta-9-THC

Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Yale University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-04
Primary Completion
2012-06-01
Completion
2012-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01591629 on ClinicalTrials.gov